News & Events

• November 29, 2023
  

  C-Path’s Translational Therapeutics Accelerator and Celdara Medical Announce Pipeline-focused MOU

  TUCSON, Ariz. and LEBANON, N.H., November 29, 2023 — Critical Path Institute’s (C-Path) Translational Therapeutics Accelerator (TRxA) and Celdara Medical today announced the signing of a Memorandum of Understanding (MOU) aimed at identifying and advancing promising new therapeutics in areas of high unmet medical need. Under the terms of this agreement, both organizations look to......
• November 9, 2023
  

  C-Path’s Pioneering Neuroscience Workshop Transforms the Landscape of Neurological Disorder Therapies

  TUCSON, Ariz., Nov. 9, 2023 – Critical Path Institute (C-Path) is pleased to announce the release of a new peer-reviewed publication, titled “Transforming Drug Development for Neurological Disorders: Proceedings from a Multi-disease Area Workshop,” now published in Neurotherapeutics, The Journal of the American Society for Experimental Neurotherapeutics. A distinguished team of C-Path scientists and patient-advocates......
• November 7, 2023
  

  C-Path’s T1D Consortium New-onset Article Published in The Lancet Diabetes and Endocrinology

  Research confirms immune-based therapies improve outcomes in new-onset T1D TUCSON, Ariz., November 7, 2023 — Critical Path Institute’s (C-Path) Type 1 Diabetes Consortium, along with external collaborators from Cardiff University and the University of Alberta, today announced the publishing of “C-peptide and metabolic outcomes in trials of disease modifying therapy in new-onset type 1 diabetes”......
• October 26, 2023
  

  C-Path and Congenital Hyperinsulinism International Announce Data Sharing Agreement

  TUCSON, Ariz., October 26, 2023 — Critical Path Institute (C-Path) and Congenital Hyperinsulinism International (CHI), a leading nonprofit dedicated to improving the lives of children and adults living with Congenital Hyperinsulinism (HI), today announced a data sharing agreement to incorporate rare disease patient-level data from CHI’s HI Global Registry into C-Path’s Rare Disease Cures Accelerator-Data......
• October 25, 2023
  

  C-Path Announces Significant Expansion in Neonatal RWD Project

  Details of the expansion will be a highlight of the Institute’s Scientific Breakthrough Summit Oct. 26-27 in D.C. TUCSON, Ariz., October 25, 2023 — Critical Path Institute’s (C-Path) International Neonatal Consortium (INC) and the Institute for Advanced Clinical Trials for Children (I-ACT) are thrilled to announce a significant expansion of neonatal data in their Real-World......